步長製藥(603858.SH):與科創醫藥簽訂補氣通絡顆粒IIa期臨牀研究補充協議
格隆匯12月25日丨步長製藥(603858.SH)公佈,近日,公司全資子公司陝西步長製藥有限公司(“陝西步長”)與北京創立科創醫藥技術開發有限公司(“科創醫藥”)簽訂了《補氣通絡顆粒IIa期臨牀研究補充協議》,對2018年5月31日雙方簽訂的《技術服務合同》進行補充,原協議由陝西步長委託科創醫藥研究開發補氣通絡顆粒治療氣虛血瘀證隨機、雙盲平行對照、多中心II期臨牀試驗項目進行臨牀試驗設計與監查管理的專項技術服務。
雙方約定:1、鑑於臨牀試驗方案設計發生重大改變,故將原合同標的“II期臨牀試驗”變更為“IIa期臨牀試驗”。
2、鑑於補氣通絡顆粒治療氣虛血瘀證隨機、雙盲平行對照、多中心IIa期臨牀試驗樣本量增加,新增客觀檢查指標以及檢查設備等,導致臨牀研究觀察費、檢查費以及CRO服務費用增加,甲方同意增加該項目臨牀研究經費,新增加相關費總額為人民幣680萬元,用於支付新增加的技術服務經費和報酬。
此次陝西步長與第三方簽訂藥品技術服務合同補充協議,有利於擴大公司藥品研發能力和範圍,一定程度上節約了公司藥品臨牀試驗的時間和成本,保障項目的順利進行。本次臨牀試驗合同金額不會對公司財務狀況和經營成果產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.